These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. [Clozapine and treatment of negative symptoms]. Lançon C; Farisse J; Llorca PM Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403 [TBL] [Abstract][Full Text] [Related]
29. [Weight gain and clozapine]. Jalenques I; Tauveron I; Albuisson E; Audy V Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282 [No Abstract] [Full Text] [Related]
30. Maintenance therapy and the natural course of schizophrenia. Davis JM J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252 [TBL] [Abstract][Full Text] [Related]
31. Butaclamol in the treatment of schizophrenia. A standard-controlled clinical trial. Nestoros JN; Lehmann HE; Ban TA Int Pharmacopsychiatry; 1978; 13(3):138-50. PubMed ID: 355181 [TBL] [Abstract][Full Text] [Related]
32. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Buckley P; Bartell J; Donenwirth K; Lee S; Torigoe F; Schulz SC Bull Am Acad Psychiatry Law; 1995; 23(4):607-11. PubMed ID: 8639988 [TBL] [Abstract][Full Text] [Related]
33. Clozapine for refractory schizophrenia: an open study of 14 patients treated up to 2 years. Mattes JA J Clin Psychiatry; 1989 Oct; 50(10):389-91. PubMed ID: 2571612 [TBL] [Abstract][Full Text] [Related]
34. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. van Berckel BN; Hijman R; van der Linden JA; Westenberg HG; van Ree JM; Kahn RS Biol Psychiatry; 1996 Dec; 40(12):1298-300. PubMed ID: 8959296 [No Abstract] [Full Text] [Related]
36. Proceedings: Penfluridol in the treatment of schizophrenia: clinical and psychometric findings. Deutsch M; Nair NP; Saarma J Psychopharmacol Bull; 1976 Jan; 12(1):34-7. PubMed ID: 1108082 [No Abstract] [Full Text] [Related]
37. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Mishara AL; Goldberg TE Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486 [TBL] [Abstract][Full Text] [Related]
38. [Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication]. Baskak SC; Ozsan H; Baskak B; Devrimci Ozgüven H; Kinikli G Turk Psikiyatri Derg; 2008; 19(1):5-12. PubMed ID: 18330738 [TBL] [Abstract][Full Text] [Related]
39. High-dose versus low-dose strategies in the treatment of schizophrenia. Kane JM; Rifkin A; Woerner M; Reardon G; Kreisman D; Blumenthal R; Borenstein M Psychopharmacol Bull; 1985; 21(3):533-7. PubMed ID: 2863848 [No Abstract] [Full Text] [Related]
40. [Problems in evaluating new antipsychotic drugs]. Fleischhacker WW Wien Med Wochenschr; 1998; 148(11-12):266-72. PubMed ID: 9746969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]